Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA accepts priority review for EYLEA injection to treat diabetic retinopathy in DME patients
The goal for a priority review is six months, for a target action date of 30 March 2015, as per the Prescription Drug User Fee Act (PDUFA). In
The goal for a priority review is six months, for a target action date of 30 March 2015, as per the Prescription Drug User Fee Act (PDUFA). In
Conducted in collaboration with the Blood Cancer Research Partnership and Dana-Farber Cancer Institute (DFCI), the trial is designed to evaluate the safety and efficacy of the combination of
Antibody-Targeted Tumor Cell Killing 20 (ATTCK20) is a combination of a patient’s antibody-coupled T-cell receptor (ACTR) T-cells administered with rituximab, a monoclonal antibody targeting CD20. ACTR is a
Under the deal, Pfizer acquired a portion of Baxter’s facility in Orth, Austria, which manufactures meningitis vaccine, NeisVac-C as well as the encephalitis vaccine, FSME-IMMUN/TicoVac. NeisVac-C is a
Around 1,500 patients in 15 countries will be enrolled in the trial which is designed to evaluate the safety and efficacy of AZD3293/LY3314814 compared with placebo in the
The new facility is aimed to boost the company’s local manufacturing capability to handle increasing demand in China for its peripheral neuropathy treatment Methycobal injection in expectation of
As part of its plans, the company has decided to focus its Osaka plant to become a specialty manufacturing site for prostate and breast cancer drug Leuplin/Lupron (leuprorelin).
The sBLA was based on an international, multi-center, double-blind, randomized, placebo-controlled Phase III trial which included around 250 adult patients with upper limb spasticity. The trial, which was
As part of the deal, UCB will manufacture and supply the product for commercialisation and Daiichi will manage the distribution and book sales. The deal, which is subject
Under the five-year deal, Cancer Research UK researchers will have access to around two million molecules in AstraZeneca’s compound library, in addition to screening tools at the facility